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1. Introduction  
Scientific literature contains numerous accounts of possible hypothalamic - pituitary axis 
dysfunction in pediatric patients with various behavioral disorders and/or 
psychopathology. However, demonstrating any consistent pattern of endocrine dysfunction 
in these behavioral areas, if indeed such even exists, remains elusive. This chapter will 
review the literature regarding possible endocrine dysfunction in pediatric patients with 
ADHD and will focus on the two areas where publications have been the most prolific 
regarding possible interactions of hormones and behavior: (1) the hypothalamic - pituitary - 
adrenocortical axis and ADHD and (2) growth in children with Attention Deficit 
Hyperactivity Disorder. The chapter will conclude with a review of growth hormone 
therapy in children with ADHD, focusing primarily on ADHD children referred for poor 
growth and growth evaluation to a pediatric endocrine practice.  
2. Hypothalamic - Pituitary - Adrenocortical Axis (HPAA) in behavior and 
ADHD 
Variations in hypothalamic - pituitary - adrenocortical axis (HPAA) activity have been 
associated with or implied as a potential causative factor in a variety of psychopathology. 
Higher cortisol levels may be seen with aggressive/impulsive behavior whereas lower cortisol 
levels correlate more often with callous unemotional (CU) behavior. For example, significantly 
higher adrenal activity, both baseline and stress challenged, is found in five year old boys 
exhibiting hyperactivity, impulsivity and emotional difficulties than is found in boys without 
such behavior (Hatzinger et al., 2007). In reviewing older children and adolescents, Barzman et 
al also found higher cortisol levels to occur more often in conjunction with impulsive 
aggressive behavior, and lower cortisol levels with CU traits (Barzman et al., 2010). Similarly, 
Stadler et al. found lower stressed salivary cortisol responses in ADHD children who exhibited 
CU traits compared to ADHD children with lower CU traits (Stadler et al., 2011).  
2.1 Dysregulation of Hypothalamic - Pituitary - Adrenocortical Axis Activity in 
behavior and ADHD 
Hypothalamic - Pituitary - Adrenocortical Axis (HPAA) activity is known to vary with 
gender and age; gender specific differences in HPAA activity are found in children as young 
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as five years old, with girls having higher baseline and stressed adrenal activity compared to 
boys (Hatzinger et al., 2007). Recent studies increasingly support the idea that at least some 
varieties of ADHD are associated with dysregulation of the HPAA axis, particularly a 
reduced response to stressful stimuli (Ma et al., 2011, Anu-Katriina et al., 2011). 
Interestingly, similar reduced HPAA activity may be also found in people following 
significant acute traumatic events or with chronic stress (Anu-Katriina et al., 2011).  
In some studies, ADHD subtypes are found to have both decreased baseline, wakening 
cortisol levels and a decreased response to stressful stimuli (Freitag et al., 2009). Freitag et. 
al. found these decreased wakening cortisol levels in ADHD children only when ADHD was 
also associated with comorbid oppositional defiant disorder (ODD). Diminished wakening 
cortisol was not observed in children with ADHD only or in children with ADHD plus 
conduct disorder or anxiety disorder (Freitag et al., 2009). In other studies, in this case 170 
elementary school-age ADHD males, no differences in baseline, waking cortisol levels 
between ADHD subtypes could be demonstrated (Hastings et al., 2009). 
In another study of 128 ADHD male children, age 6 – 14 years, Ma et. al. found that ADHD 
children with hyperactive impulsive traits (ADHD-HI) had significantly lower baseline (8:00 
am) cortisol levels than in children with either ADHD-predominantly inattention type 
(ADHD-I) or ADHD-combined type (ADHD-C) (Ma et al., 2011). Further, the ADHD group 
as a whole had significantly lower baseline (8:00 am) cortisol levels compared to non-ADHD 
controls (226.47±129.12 nmol/L ADHD vs. 384.53±141.43 nmol/L controls, P<0.001. Despite 
these differences in cortisol levels, there were no significant corresponding differences in 
ACTH levels between the ADHD group as a whole vs. the non-ADHD control group (P>0.05).  
Cortisol, a hormonal product of the adrenal glands, can be used as an indicator of  
hypothalamic - pituitary - adrenal -axis (HPAA)  activity. In the above referenced study, 
lower cortisol levels in the ADHD group compared to non-ADHD controls without 
concurrent differences in ACTH secretion suggest a general disinhibition or dysfunction 
(under-reactivity) of HPAA activity in ADHD children as opposed to the general 
population. Finally, no differences were found in ACTH values between the various sub-
groups of ADHD (P>0.05), despite the lower cortisol values found in the ADHD-HI 
subgroup, suggesting that even among patients with ADHD, some exhibit greater HPAA 
disinhibition than others (Ma et al., 2011). 
Mothers of 272 eight-year-old children with ADHD were asked to rate their child's ADHD 
related behavior using such standard methods as the ADHD-IV Rating Scale and the Child 
Behavior Checklist (CBCL). The mothers' responses were then compared to diurnal salivary 
cortisol levels from the children in an attempt to correlate behavior with baseline, unstressed 
salivary cortisol. In contrast to some of the previously referenced studies, no correlations nor 
significant associations were found between unstressed diurnal cortisol levels and 
behavioral symptoms. Stressed, salivary cortisol responses to the Trier Social Stress Test for 
Children (TSST-C) were next evaluated, and differential stress responses were found, again 
suggesting dysregulated HPAA activity. Lower cortisol stress responses were seen in 
ADHD males with higher degrees of inattentive symptoms (ADHD-I) than in other ADHD 
males. Similarly, ADHD-I females had a more rapid fall in stress cortisol response than did 
other non-ADHD-I females (Anu-Katriina et al., 2011).  
Perhaps not surprising and again emphasizing mind-body connection. increased stressed 
cortisol levels in response to venipuncture are greater in some ADHD children with 
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coexisting anxiety disorders than in those with comorbid disruptive behavior or 
oppositional problems (Hastings et al., 2009).  
A summary of selected studies of the hypothalamic - pituitary - adrenocortical axis activity 
and associated behavior is presented in Table 1. The table compares the patient populations 
studied, the endocrine activity measured, associated diagnosis or behavioral traits selected by 
the researchers, and the qualitative results. Qualitative results are presented, rather than 
quantitative findings, in order to better compare and appreciate the differences in the studies.  
2.2 Summary and therapeutic considerations 
In summary, studies of hypothalamic - pituitary - adrenocortical axis activity in ADHD 
children have yielded conflicting results, likely due to the confounding variables of 
comorbidities, subtypes and heterogeneity of ADHD (Hastings et al., 2009); the variety of 
methods used to assess stress hormone activity; and current psychosocial conflicts such as 
parenting issues, family conflicts and stressful, acute life events, all of which can increase 
cortisol levels (Freitag et al., 2009) and affect the outcome of studies of hormonal levels and 
behavior. If further research is able to better clarify this complex interaction, measurements 
of hormonal levels may become a useful diagnostic adjunct to help select the most 
appropriate treatment modalities for pediatric behavioral disorders and aggression 
(Barzman et al., 2010). 
 
Reference Patient 
Population  
Endocrine Diagnosis or Associated 
Behavioral Traits 
Result 
Hatzinger 
et al., 2007 
102 five-year 
olds, (59 boys, 
43 girls) 
Baseline 
adrenal 
activity 
hyperactivity, impulsivity 
and emotional problems 
(boys); positive emotions 
(girls)  
Increased adrenal 
activity vs. controls 
 102 five-year 
olds, (59 boys, 
43 girls) 
Stress 
challenged 
adrenal 
activity 
hyperactivity, impulsivity 
and emotional problems 
(boys); positive emotions 
(girls) 
Increased adrenal 
activity vs. controls 
Freitag et 
al., 2009 
128 ADHD age 
6–13 years; 96 
control age 6–
12 years 
Cortisol 
awakening 
response  
ADHD with and without 
comorbid oppositional 
defiant (ODD), conduct, 
or anxiety disorders 
Decreased cortisol 
in ADHD with 
ODD group vs all 
other subgroups or 
controls 
 128 ADHD age 
6–13 years  
Cortisol 
awakening 
response  
ADHD with and without 
current psychosocial risk 
/ stress factors 
Increased cortisol 
with adverse 
parenting, family 
conflicts, acute life 
events  
Hastings 
et al., 2009 
170 ADHD 
boys, 
elementary 
school-age 
Salivary 
cortisol at 
waking, 
baseline 
ADHD with and without 
comorbid disruptive 
behavior and anxiety 
disorders 
No differences in 
wakening, baseline 
cortisol levels 
between subgroups 
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 170 ADHD 
boys, 
elementary 
school-age 
Salivary 
cortisol post 
stress 
ADHD with and without 
comorbid disruptive 
behavior and anxiety 
disorders 
Increased post 
stress cortisol in 
ADHD with 
anxiety disorders 
Barzman 
et al., 2010 
children and 
adolescents 
Cortisol  impulsive, aggressive 
traits 
Increased cortisol 
concentrations 
 children and 
adolescents 
Cortisol callous, unemotional 
traits  
Decreased cortisol 
concentrations 
Stadler et 
al., 2011 
36 boys with 
ADHD, age 
8– 14 years 
Salivary 
cortisol, pre 
and post 
stress  
higher callous, 
unemotional 
traits vs. lower CU traits  
Decreased HPAA 
activity in higher 
ADHD-CU vs. 
lower ADHD-CU 
Ma et al., 
2011 
boys with 
ADHD, 6–14 
years old  
Baseline 8:00 
am Cortisol 
ADHD with hyperactive 
(HI); inattention (I); or 
combined traits 
Lowest baseline 
cortisol in ADHD-
HI vs. ADHD-I or 
ADHD combined 
traits 
 boys with 
ADHD, 6–14 
years old 
ACTH levels ADHD with hyperactive 
(HI); inattention (I); or 
combined traits 
No difference in 
ACTH between 
subgroups 
 boys age 6–14 
years old  
Baseline 8:00 
am Cortisol 
ADHD vs. non-ADHD 
controls 
Lower baseline 
cortisol in ADHD 
vs. non-ADHD 
 boys age 6–14 
years old  
ACTH levels ADHD vs. non-ADHD 
controls 
No difference in 
ACTH in ADHD 
vs. controls 
Anu-
Katriina et 
al., 2011 
272 ADHD, 
age eight years
Diurnal 
salivary 
cortisol  
ADHD-IV Rating Scale 
and the Child Behavior 
Checklist (CBCL) 
No associations 
between behavioral 
symptoms and 
diurnal cortisol 
levels. 
 272 ADHD, 
age eight years
Salivary 
cortisol post 
stress  
ADHD-IV Rating Scale, 
CBCL, Trier Social Stress 
Test for Children (TSST-
C) 
Lower stressed 
cortisol in boys and 
girls with 
predominant 
ADHD-I 
Abbreviations: ADHD = attention deficit hyperactivity disorder; ADHD-CU = ADHD with callous 
unemotional traits; ADHD-HI = ADHD with hyperactive impulsive traits; ADHD-I = ADHD-
predominantly inattention type; ADHD-C = ADHD-combined type 
Table 1. Hypothalamic - Pituitary - Adrenocortical Axis (HPAA) Activity in Behavior and 
ADHD 
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3. Growth in children with ADHD 
3.1 Growth in non-medically treated ADHD children 
Children with ADHD, with or without stimulant therapy, may have significantly decreased 
height, head circumference, percent body fat, and abdominal circumference,(Ptacek et al., 
2009a, 2009b). In two studies Ptacek and colleagues demonstrated decreased nutritional 
status and lower stature in ADHD children compared to population normals. First, a 
comparison of non-medicated ADHD boys (n=46, average age 11.03 years) found 
significantly decreased percent body fat and height in a non-treated ADHD population 
(Ptacek et al., 2009a). Next, anthropometric measurements, including height, head 
circumference, percent body fat, and abdominal circumference, were determined in both 
medically-treated and non-treated ADHD boys (n=104, age 4-16 years). These 
measurements in the treated and non-treated groups were compared to a normal, non-
ADHD population and demonstrated decreased percent body fat and abdominal 
circumference (markers for nutritional status) as well as decreased height and head 
circumference in the ADHD population vs. the population norms (p<0.01) regardless of 
treatment status (Ptacek et al., 2009b), suggesting that dysregulated growth may be caused 
by or at least associated with ADHD itself, independent of other factors. 
In a review of 124 ADHD boys, height deficits were found only in early adolescent aged 
boys with ADHD. This early adolescent decline in growth then spontaneously improved by 
later adolescence or adulthood with no apparent effect on adult height. Although 89% of the 
ADHD patients had a history of pharmacologic therapy at some point, height deficits were 
unrelated to stimulant medication use or weight loss. The mean height SDS of the ADHD 
group was 0.21 compared to 0.47 in the controls (p = 0.03), and the adolescent aged related 
decline amounted to a mean height deficit of 2.1 cm compared to controls (Spencer et al., 
1998).  
3.2 Growth in stimulant medication treated ADHD children 
Reductions in height, weight and / or body mass index are commonly reported with 
stimulant therapy use for ADHD (Faraone et al., 2008, Negrao & Viljoen, 2011), and may be 
worse in larger children, those who are naive to therapy or who have a greater cumulative 
exposure to stimulants (Faraone et al., 2010). Ptacek et al. found a lower percent body fat in 
medically treated ADHD males (age 4 – 16 years) as compared to non-treated peers (Ptacek 
et al., 2009b).  
A quantitative review of published, longitudinal studies of stimulant-treated ADHD 
children found significant delays in height and weight over at least of year of treatment time 
(Faraone et al., 2008). To determine if such decreased growth also occurs in typical clinical 
scenarios in which patients are treated for longer periods of time in outpatient settings, the 
heights and weights of 84 ADHD children treated for two - three years continuously with 
methylphenidate from two community pediatric practices were examined. Growth 
parameters in treated ADHD children were compared to those of near-same age-matched, 
healthy siblings who did not have ADHD nor any other chronic condition. Height standard 
deviation (SD) scores were determined from at least one year prior to starting therapy and 
thereafter during therapy. Heights were similar pretreatment between boys with ADHD 
and their age-matched, non-ADHD siblings. During treatment, the height SD scores and 
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growth velocity of the methylphenidate treated boys declined while those of their siblings 
did not decline and remained constant or even increased. Methylphenidate treated girls 
showed similar decline in growth. Over time, treated ADHD boys lost about 0.5 SD in 
height (roughly 3-4 cm), and treated girls lost about 0.6 SD (3-4 cm) in height compared to 
age-, time- and gender-matched siblings. A clear dose-response curve of methylphenidate 
dose vs. growth decline was not found, and the authors did not address growth in non-
stimulant medication treated ADHD children. However, this study did document a clear 
decline in growth over time in treated children seen in general practice (Lisska & Rivkees, 
2003).  
Other studies have found more mild and transient growth disruptions in ADHD children 
(Negrao & Viljoen 2011), and that even with stimulant treatment, associated growth 
deceleration and loss of expected height may amount to only a one to two centimeter deficit 
per year during treatment (Poulton, 2005, Drappatz et al., 2006). Comparison of paired height 
measurements, before and after ADHD treatment, suggest a height deficit of only about 1 
cm/year during the first 1 to 3 years of ADHD treatment (Pliszka, 1998). Growth delay may 
also be dose dependent during treatment, normalizing afterwards (Faraone et al., 2008) with 
no long-term adverse effect even with high dose, aggressive stimulant therapy (Pliszka, 1998).  
3.3 Side effects of stimulant medications and possible causes of growth delay 
One of the most frequently reported side effects of stimulant medication use for ADHD is 
loss of appetite. Other commonly reported and usually relatively minor complaints include 
headaches, disturbances in mood and other emotional problems, stomach upset, sleep 
disturbances, and rashes (Tobaiqy et al., 2011). Far less common, but obviously more 
serious, concerns regarding stimulant medication use include suicidal ideation and sudden 
cardiac death (Graham et al., 2011). 
Interestingly, although a controversial area among physicians and the subject of multiple 
scientific studies, growth delay was not a reported concern in a survey of parents of children 
and adolescents receiving stimulant medical therapy (methylphenidate) for ADHD (Tobaiqy 
et al., 2011).  
The exact mechanism by which stimulant medication affects growth is unclear, but possibly 
includes decreased appetite with subsequent poor weight gain (Poulton, 2005). Since 
decreased or loss of appetite is a common complaint, It is tempting to ascribe decreased 
stature as a secondary consequence of stimulant-induced malnutrition. However, despite 
loss of appetite being reported in as many as 34.3% of treated ADHD patients (Tobaiqy et 
al., 2011), actual weight loss is not a consistent finding among ADHD studies. While varying 
degrees of weight loss are found in some patient populations, other studies report no weight 
loss. Similarly, it has not been possible to convincingly demonstrate an association between 
decreased nutrition and subsequent poor height growth in ADHD reports (Spencer et al., 
1998).  
Other possible mechanisms for poor growth include decreased bone mineralization, 
maturation and linear growth (Lahat et al., 2000), or a medication-induced disruption of the 
hypothalamic - pituitary - IGF-I axis (Negrao & Viljoen, 2011). Adrenergic stimulants are 
known to increase dopamine and noradrenaline in neural synapses. Increased dopamine 
and noradrenaline may in turn inhibit the secretion of growth hormone (GH) and other 
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growth-related peptides including thyroid hormones, sex hormones, prolactin and insulin, 
ultimately resulting in growth suppression (Negrao & Viljoen, 2011). However, studies of 
growth hormone have not shown a consistent altered pattern of GH secretion in association 
with stimulant treatment (Spencer et al.,1998). Finally, dysregulation of various 
neurotransmitters, in particular the catecholamines, is associated with ADHD itself. Such 
dysregulation may alter hypothalamic - pituitary function and cause growth delay, even in 
the absence of stimulant treatment (Spencer et al.,1998).  
3.4 Concerns regarding growth studies in ADHD 
Despite many, and at times, conflicting reports of slow growth in children and adolescents 
with ADHD (Frindik et al., 2009) and theoretical concerns of adverse interactions between 
ADHD and the hypothalamic-pituitary-IGF-I axis (Jensen & Garfinkel, 1988), no intrinsic 
defect or consistent dysfunction in this axis in ADHD has been identified. However, the 
following caveats regarding studies of growth in ADHD must be kept in mind. Rigorous 
scientific investigations of growth in children with ADHD have been relatively rare, the 
majority of ADHD studies are of a retrospective nature and lack significant power, adequate 
controls, sufficient follow up time, or stringent statistical analysis to draw firm conclusions 
(Poulton, 2005, Drappatz et al., 2006). Identifying appropriate age, gender, socio-economic, 
and diagnosis-matched control populations to study growth in ADHD patients with and 
without stimulant treatment may be especially problematic due to inherent treatment bias. 
The use of stimulant medication in children with ADHD varies by gender, race, age, 
language spoken in the home, insurance status, and contact with health care providers 
(Visser et al., 2007). The frequency with which ADHD medication is used for any reason also 
varies by geographic location, ranging from 2.1% of the general pediatric population in 
California to 6.5% in Arkansas (CDC, 2003). ADHD medical treatment is more likely to be 
used in males than females of all ages, and used more often in non-Hispanic, English-
speaking, insured children than other groups (CDC, 2003, Visser et al., 2007). Cognizant of 
these difficulties, Drappatz and colleagues in 2006 reviewed 845 published articles on 
ADHD and growth, and concluded that usable data for a meta-analysis review could be 
extracted from only 22 (2.6%) of published studies (Drappatz et al., 2006).  
The pathophysiology of ADHD itself is poorly understood (Spencer et al.,1998). It is likely 
therefore that the ADHD population in many studies is actually fairly heterogenous, further 
adding to the problems of patient selection for population studies and the selection of 
appropriate controls.  
Because of the difficulties sited above, the actual long-term growth effects, if any, of ADHD 
or its treatment have remained unclear and controversial ( Spencer et al.,1998, Pliszka, 1998, 
Poulton, 2005, Negrao & Viljoen, 2011). Recently, however, long-term, case control data have 
begun to emerge on final adult heights in ADHD. Biederman and colleagues studied the 
effect of ADHD and stimulant treatment using longitudinal, case-control studies of male 
and female children with ADHD (n = 137) compared to control children without ADHD (n = 
124) followed for 10–11 years into adulthood. Compared to the control children, there were 
no differences in any growth outcomes in the ADHD group, regardless of stimulant 
treatment or the lack thereof (Biederman et al., 2010). A summary of growth studies in 
ADHD children and adolescents, some with no medical treatment and some treated with 
psychostimulant medications, is presented in table 2. 
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 Reference
Patient 
Population
Study Details Result 
ADHD, No 
Stimulant 
Treatment 
    
 Lisska & 
Rivkees, 
2003 
ADHD vs. age- and 
gender-matched, 
non ADHD 
siblings, 
Height, weight, 
and BMI prior to 
ADHD stimulant 
treatment  
No significant 
differences in height SDS 
between matched 
ADHD and non-ADHD 
siblings  
 Ptacek 
et al., 
2009a 
ADHD males 
(n=46, ave. age 
11.03 years) vs. 
control, non-ADHD
Anthropometric 
measurements 
Decreased percent body 
fat and height in ADHD 
vs. non-ADHD 
 Biederma
n 
et al., 
2010 
ADHD males and 
females (n=137) vs. 
control, non-ADHD 
(n=124) 
Case-controlled 
study, 
longitudinal 10-
11 year follow-
up  
No differences in height 
trajectories or in any 
growth parameters at 
follow-up 
 Ptacek 
et al., 
2009b 
ADHD males 
(treated and non-
treated, n=104, age 
4-16 years) vs. 
control, non-ADHD
Anthropometric 
measurements 
Decreased percent body 
fat, abdominal 
circumference, height, 
head circumference, 
ADHD vs. non-ADHD  
ADHD with 
Stimulant 
Treatment 
    
 Spencer 
et 
al.,1998 
ADHD males (89% 
treated at some 
time and 11% non-
treated, n=124) vs. 
control, non-ADHD 
(n=109) 
Anthropometric 
measurements 
Mean height deficit of 
2.1 cm in early 
adolescent ADHD males 
vs. controls. 
Mean height SDS 0.21 
(ADHD) vs. 0.47 
(controls), p = 0.03  
 Lahat 
et al., 
2000 
Methylphenidate 
treated ADHD vs. 
control, non 
ADHD, 1-2 years of 
treatment  
Dual photon 
absorptiometry, 
serum alkaline 
phosphatase, 
urinary 
deoxypyridinoline
No differences in bone 
mineral density turnover 
in treated ADHD vs. 
controls  
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 Lisska & 
Rivkees, 
2003 
Methylphenidate 
treated ADHD vs. 
age- and gender-
matched, non 
ADHD siblings, 2-3 
years treatment 
duration  
Height, weight 
and BMI; pre-
treatment and up 
to 3 years during 
treatment  
Decreased height 
velocity during 
treatment; overall loss of 
0.5 SDS height (boys) 
and 0.6 SDS height 
(girls)  
 Drappatz
et al., 
2006 
Variable age ranges Meta-analysis 
review of 22 
studies 
1 - 2 cm / year height 
deficit per year of 
ADHD treatment 
 Poulton, 
2005 
Variable age ranges Medline search 
and review of 29 
studies 
One cm / year height 
deficit, during 1-3 three 
years of ADHD 
treatment 
 Frindik 
et al.,  
2009 
Prepubertal, male 
and female, treated 
ADHD vs. non - 
ADHD  
Retrospective 
review of GH 
registry, pre-GH 
treatment data 
Decreased BMI in 
treated ADHD; No 
difference in mean 
height SDS or growth 
rates prior to GH 
treatment 
 Biederma
n 
et al., 
2010 
Males and females; 
psychostimulant 
treatment ADHD 
vs. control, non-
ADHD 
Longitudinal, 
case-controlled 
study, linear 
growth, 10-11 
year follow-up  
No differences in growth 
in ADHD with 
psychostimulant 
treatment vs. controls 
 Faraone 
et al., 
2010 
LDX treated ADHD 
children (n=281), 
ages 6 to 13 years 
Longitudinal, 
height, weight, 
BMI, up to 15 
months 
treatment  
Decreased gains in 
height, weight, BMI vs. 
expected from CDC 
standards  
 Rose 
et al., 
2011 
Treated ADHD 
(n=1055) vs. non - 
ADHD (n= 6319) 
Review of GH 
registry, pre-GH 
treatment data 
No difference in mean 
height SDS treated 
ADHD vs. non-ADHD 
prior to GH treatment 
 
Abbreviations: ADHD, attention deficit hyperactivity disorder; n = number, BMI, body mass index; GH, 
growth hormone; SDS, standard deviation score, LDX = .lisdexamfetamine dimesylate, CDC = Centers 
for Disease Control. 
 
 
Table 2. Growth in Children with ADHD 
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4. Growth hormone treatment of ADHD associated short stature 
As the preceding section discusses, the majority of children with ADHD have, at worst, 
mild, perhaps stimulant therapy-related, growth delays, ultimately achieving normal 
heights and weights. However, a subgroup of ADHD patients seems to exist that does have 
clinically significant and concerning growth delay. Spencer and colleagues found that 10% 
of ADHD boys in their review of 124 patients had height SD scores of more than 2 SD's 
below the mean. Using the same height SD cutoff criteria, only 1% of their control non-
ADHD population was this short (Spencer et al.,1998).  
The characteristics and natural history of this more growth delayed ADHD subgroup are 
not well defined. Their documented existence, however, supports our clinical impressions 
that at least some ADHD-treated children have growth delays that are sufficient to warrant 
investigation by a pediatric endocrinologist. In point of fact, our pediatric endocrine practice 
has seen a steadily increasing number of ADHD-treated children referred for evaluation of 
delayed growth and possible growth hormone therapy. Anecdotally, such children, if 
treated with recombinant human growth hormone (GH), did not seem to respond as well to 
GH therapy as children receiving GH therapy alone, suggesting that ADHD treatment 
might be a relative contraindication to GH therapy. 
We undertook a retrospective analysis of children enrolled in a national growth hormone 
patient registry (Genentech's National Cooperative Growth Study (NCGS)) database (1985-
2005) to determine (1) the frequency of ADHD treatment among children who are also 
receiving GH, (2) if any differences existed in either biochemical testing or anthropometrics 
between ADHD and non-ADHD, and (3) the first-year growth response in children 
receiving GH therapy only vs. those receiving GH therapy plus an ADHD medication 
(Frindik et al., 2009).  
4.1 Frequency of ADHD medication use in growth hormone treated children  
Both the absolute number of children receiving both ADHD treatment and growth hormone 
and the percentage of such enrolled in the national growth registry increased over a twenty 
year period. During the first year of the NCGS registry (1985), out of 850 patients receiving 
GH therapy, only 7 (0.8%) were receiving concurrent ADHD medications. Twenty years 
later (2005), of 12,113 enrolled patients on GH therapy, 752 (5.8%) were also receiving 
ADHD treatment. Reasons for this increase were felt to include: 1) an increased incidence of 
ADHD and/or an increased use of ADHD medication within the general pediatric 
population (CDC 2003, Froehlich et al., 2007) that could then be reflected in the NCGS 
database and 2) a referral bias in growth registries (Finkelstein et al., 1998, Kemp, 2006) that 
possibly leading to some overlap between the GH-treated and the ADHD-treated 
populations (Visser et al., 2007).  
4.2 Endocrine function and growth in ADHD children prior to GH treatment 
To examine differences in hypothalamic - pituitary - growth hormone axis activity in non-
ADHD as compared to ADHD children, children were divided into two groups on the basis 
of their response to GH stimulation testing. Children were considered to have idiopathic 
GH deficiency (IGHD) if their maximum stimulated growth hormone (MSGH) response to 
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provocative stimuli was less than 10 ng/ml, or idiopathic short stature (ISS) if the MSGH 
response was equal to or greater than 10 ng/ml and no other syndrome or diagnosis given. 
Once divided into these two groups (IGHD and ISS), we found no distinguishing 
characteristics in hypothalamic - pituitary - growth hormone axis activity: mean MSGH 
(ng/ml) responses were similar in both the ADHD-treated and non-ADHD-treated groups. 
4.3 Anthropometrics 
The two groups were also similar as regards pre-treatment anthropometric measurements, 
although the ADHD-treated populations, both IGHD and ISS, were thinner (mean –0.4 BMI 
standard deviation scores (SDS) for IGHD and –0.4 BMI SDS for ISS) than the non–ADHD-
treated, presumably an effect of the ADHD medication on appetite and weight. This 
difference in BMI was not reflected in height, as there was no statistically significant 
difference between mean baseline height SDS with and without ADHD treatment. Mean 
baseline height SDS with ADHD treatment was –2.6 and without ADHD treatment –2.7.  
4.4 Response to GH treatment 
When adjusted for age, sex, and enrollment body mass index, the difference in first-year 
GH-treatment response for children with IGHD was similar regardless of ADHD therapy. 
Mean first year growth rate for ADHD-treated IGHD was 8.5±2.0 cm/yr vs 9.4±2.6 cm/yr 
for non-ADHD-treated IGHD, a slightly less, but clinically insignificant difference. 
Similarly, first-year growth response was clinically indistinguishable between the ISS 
groups: 8.1±1.9 cm/yr (ADHD treatment) vs 8.6±2.1 cm/yr (ISS without ADHD treatment).  
4.4.1 Other GH registry based studies of GH treatment in ADHD 
Rao and colleagues reviewed the impact of ADHD treatment on the response to GH therapy 
over a longer treatment time, comparing IGHD and ISS children receiving GH plus either 
methylphenidate and pemoline to the response to GH alone over a mean treatment time of 
2.7 to 3.0 years. Enrollment, pre-GH treatment height SD scores were similar in the ADHD 
treated groups and non-ADHD groups. Treatment with methylphenidate and pemoline had 
a minor effect on the change in height SDS with GH treatment in the IGHD group. 
However, not only was this negative effect minor in the first place, but the degree of 
differential response between the ADHD-IGHD-GH group and the IGHD-GH only group 
decreased the longer GH treatment was used. No differences were seen in the response to 
GH therapy in the two ISS groups. Enrollment heights and responses to GH therapy are 
presented in Table 3.  
Another GH registry review of ADHD treated children followed for 3 years of GH therapy 
also demonstrated a similar response to GH therapy regardless of the status of ADHD 
treatment.  
Children naive to GH therapy were divided into two groups: those receiving concomitant 
ADHD medication (ADHDm) and those receiving GH only. Diagnoses of patients 
receiving GH only included GH deficiency, multiple pituitary hormone deficiency, Turner 
syndrome, Noonan syndrome, small for gestational age, and idiopathic or other short 
stature. Mean height standard deviation scores (SDS) in the two groups were similar at 
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Reference 
Patient 
Population 
Treatment 
Status 
Study Parameters
Published Results 
mean ± SD 
Rao et al., 
1998  
IGHD with 
treated ADHD 
vs. non-
ADHD IGHD 
methylphenidate 
or pemoline in 
ADHD 
Pre-GH treatment
height SDS 
– 2.8 ± 0.7 (ADHD) vs. 
– 3.0 ± 0.9 (non-ADHD) 
 n=184 
(ADHD); 
n=2313 (IGHD)
methylphenidate 
or pemoline in 
ADHD plus GH
Change in height 
SDS after GH 
treatment 
1.2 ± 0.8 (ADHD) vs. 
1.3 ± 0.9 (non-ADHD) 
 ISS with 
treated ADHD 
vs. non-
ADHD ISS  
methylphenidate 
or pemoline in 
ADHD 
Pre-GH treatment
height SDS 
– 2.8 ± 0.7 (ADHD) vs. 
– 2.9 ± 0.7 (non-ADHD) 
 n=117 
(ADHD); 
n=1283 (ISS) 
methylphenidate 
or pemoline in 
ADHD plus GH
Change in height 
SDS after GH 
treatment 
1.0 ± 0.7 (ADHD) vs. 
1.1 ± 0.7 (non-ADHD) 
Frindik 
et al.,  
2009 
IGHD with 
treated ADHD 
vs. non-
ADHD IGHD 
stimulant 
treatment in 
ADHD 
Pre-GH growth rate 
cm/yr 
3.8 ± 1.8 (ADHD) vs. 
4.4 ± 2.3 (non-ADHD) 
 n= 263 
(ADHD); 
n=6223 (IGHD)
stimulant 
treatment in 
ADHD plus GH
Growth Rate cm/yr 
after one year of 
GH 
8.5 ± 2.0 (ADHD) vs. 
9.4 ± 2.6 (non-ADHD) 
 ISS with 
treated ADHD 
vs. non-
ADHD ISS  
stimulant 
treatment in 
ADHD 
Pre-GH growth rate 
cm/yr 
4.1 ± 1.9 (ADHD) vs. 
4.4 ± 2.0 (non-ADHD) 
 n= 121 
(ADHD); 
n=2695 (ISS) 
stimulant 
treatment in 
ADHD plus GH
Growth Rate cm/yr 
after one year of 
GH 
8.1 ± 1.9 (ADHD) vs. 
8.6 ± 2.1 (non-ADHD) 
Rose 
et al.,  
2011 
Patients 
receiving up to 
3 years of GH 
treatment; 
n = 314 
(ADHD); 
n = 1583 (GH 
only) 
stimulant 
treatment in 
ADHD plus GH 
vs. non-ADHD 
with GH only 
Change in height 
SDS after 3 years 
GH 
1.14 ± 0.60 (ADHD + 
GH) vs. 
1.26 ± 0.79 (non-ADHD) 
Abbreviations: ADHD = attention deficit hyperactivity disorder; IGHD = idiopathic growth hormone 
deficiency; ISS = idiopathic short stature; n = number; SD = Standard Deviation; SDS = Standard 
Deviation Score.  
Table 3. Effects of Growth Hormone (GH) on Growth in ADHD from Retrospective Reviews 
of GH Registries 
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start of therapy: –2.3 ADHDm group vs. –2.2 GH only group. Mean BMI was also 
comparable between the groups both at enrollment and during treatment. The ADHDm 
had lower mean change (improvement) in height SDS at 4 months, 1 year, 2 years and 3 
years of GH therapy compared to the GH-only group, but the differences were minor and 
felt to be of no clinical significance. After three years of GH treatment, the change in mean 
height SDS of the ADHDm group was 1.14 compared to 1.26 of the GH-only group. 
Furthermore, 83% of patients on GH therapy plus concomitant ADHD medical treatment 
achieved a height in the normal range (greater than – 2 SDS), a response similar to the 
non-ADHD, GH-only group in whom 85% of children achieved a height greater than – 2 
SDS (Rose et al., 2011).  
See Table 3 for a summation of pretreatment data (either enrollment heights or growth 
velocity, when available) and the effects of GH therapy (either change in height or growth 
rate) in these three reviews.  
5. Conclusion 
The retrospective nature and referral bias of growth registries (Blethen et al., 1996) prevent 
extrapolation of these results to the general ADHD population. However, matched, ADHD-
treated and non-treated populations are similar enough as regards pre-treatment 
anthropometric measurements, growth hormone stimulation results, and overall response to 
GH therapy to support the idea that there is no inherent hypothalamic - pituitary - growth 
hormone dysfunction in ADHD that would interfere significantly with GH therapy.  
Finally, ADHD medical therapy should not exclude GH treatment if a child is otherwise 
an appropriate candidate for GH therapy. Such children should be expected to respond to 
GH regardless of concurrent ADHD treatment, many with first-year growth rates very 
similar to matched, non-ADHD children (Frindik et al., 2009). While it is true that some 
children with concurrent ADHD treatment may have a slightly decreased response during 
GH therapy, the effect is minor and of little clinical significance (Rao et al., 1998), and the 
overwhelming majority ultimately achieve heights in the normal range with GH therapy 
(Rose et al., 2011).  
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